Pharmacology of adenosine receptors: the state of the art

PA Borea, S Gessi, S Merighi… - Physiological …, 2018 - journals.physiology.org
Adenosine is a ubiquitous endogenous autacoid whose effects are triggered through the
enrollment of four G protein-coupled receptors: A1, A2A, A2B, and A3. Due to the rapid …

Endocannabinoids and endocannabinoid-related mediators: Targets, metabolism and role in neurological disorders

FA Iannotti, V Di Marzo, S Petrosino - Progress in lipid research, 2016 - Elsevier
The endocannabinoid system (ECS) is composed of two G protein-coupled receptors
(GPCRs), the cannabinoid CB1 and CB2 receptors, and the two main endogenous lipid …

[HTML][HTML] Cannabinoids and epilepsy

EC Rosenberg, RW Tsien, BJ Whalley, O Devinsky - Neurotherapeutics, 2015 - Elsevier
Cannabis has been used for centuries to treat seizures. Recent anecdotal reports,
accumulating animal model data, and mechanistic insights have raised interest in cannabis …

Discriminating schizophrenia using recurrent neural network applied on time courses of multi-site FMRI data

W Yan, V Calhoun, M Song, Y Cui, H Yan, S Liu… - …, 2019 - thelancet.com
Background Current fMRI-based classification approaches mostly use functional
connectivity or spatial maps as input, instead of exploring the dynamic time courses directly …

[HTML][HTML] Presynaptic adenosine receptor heteromers as key modulators of glutamatergic and dopaminergic neurotransmission in the striatum

S Ferré, LI Sarasola, C Quiroz, F Ciruela - Neuropharmacology, 2023 - Elsevier
Adenosine plays a very significant role in modulating striatal glutamatergic and
dopaminergic neurotransmission. In the present essay we first review the extensive …

Mechanisms of action and persistent neuroplasticity by drugs of abuse

ER Korpi, B den Hollander, U Farooq… - Pharmacological …, 2015 - ASPET
Adaptation of the nervous system to different chemical and physiologic conditions is
important for the homeostasis of brain processes and for learning and remembering …

Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson's disease

MT Armentero, A Pinna, S Ferré, JL Lanciego… - Pharmacology & …, 2011 - Elsevier
Several selective antagonists for adenosine A2A receptors (A2AR) are currently under
evaluation in clinical trials (phases I to III) to treat Parkinson's disease, and they will probably …

The Pharmacological Potential of Adenosine A2A Receptor Antagonists for Treating Parkinson's Disease

A Mori, JF Chen, S Uchida, C Durlach, SM King… - Molecules, 2022 - mdpi.com
The adenosine A2A receptor subtype is recognized as a non-dopaminergic
pharmacological target for the treatment of neurodegenerative disorders, notably …

Interactions of the opioid and cannabinoid systems in reward: Insights from knockout studies

K Befort - Frontiers in pharmacology, 2015 - frontiersin.org
The opioid system consists of three receptors, mu, delta, and kappa, which are activated by
endogenous opioid peptides (enkephalins, endorphins, and dynorphins). The endogenous …

Adenosine receptor control of cognition in normal and disease

JF Chen - International review of neurobiology, 2014 - Elsevier
Adenosine and adenosine receptors (ARs) are increasingly recognized as important
therapeutic targets for controlling cognition under normal and disease conditions for its dual …